Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kδ/casein...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Clin Oncol
Main Authors: Fowler, Nathan H., Samaniego, Felipe, Jurczak, Wojciech, Ghosh, Nilanjan, Derenzini, Enrico, Reeves, James A., Knopińska-Posłuszny, Wanda, Cheah, Chan Y., Phillips, Tycel, Lech-Maranda, Ewa, Cheson, Bruce D., Caimi, Paolo F., Grosicki, Sebastian, Leslie, Lori A., Chavez, Julio C., Fonseca, Gustavo, Babu, Sunil, Hodson, Daniel J., Shao, Spencer H., Burke, John M., Sharman, Jeff P., Law, Jennie Y., Pagel, John M., Miskin, Hari P., Sportelli, Peter, O'Connor, Owen A., Weiss, Michael S., Zinzani, Pier Luigi
格式: Artigo
語言:Inglês
出版: Wolters Kluwer Health 2021
主題:
RAPID COMMUNICATIONS
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8148421/
https://ncbi.nlm.nih.gov/pubmed/33683917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.03433
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍